Identification and management of hereditary breast-ovarian cancers (2004 update);Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à jour 2004)

Pathologie Biologie

Volumn 54, Issue 4, 2006, Pages 230-250

  Eisinger, F ^a,b   Bressac, B ^c,d   Castaigne, D ^c   Cottu, P H ^e   Lansac, J ^f   Lefranc, J P ^g   Lesur, A ^h   Nogues C ⁱ   Pierret, J ^j   Puy Pernias, S ^k   Sobol, H ^a,b   Tardivon, A ^l   Tristant, H ^m   Villet, R ^e  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UPR 2169 CNRS   (France)

^e GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^f CHU BRETONNEAU   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ CENTRE RENÉ HUGUENIN   (France)

^j CNRS   (France)

^k INSTITUT SAINTE CATHERINE   (France)

^l INSTITUT CURIE   (France)

^m Institut de Radiologie de Paris   (France)

more..

Author keywords

BRCA1; BRCA2; Breast cancer; Guidelines; Ovarian cancer; Preventive care; Recommendations

Indexed keywords

AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; RALOXIFENE; TAMOXIFEN; TIBOLONE;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; CONTRACEPTION; CORRELATION ANALYSIS; FAMILIAL CANCER; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARY CANCER; PHENOTYPE; PROPHYLAXIS; QUALITY OF LIFE; RISK ASSESSMENT; BREAST TUMOR; CONFIDENTIALITY; DOCTOR PATIENT RELATION; FEMALE; FRANCE; GENETICS; MASTECTOMY; OVARY TUMOR; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CONFIDENTIALITY; FEMALE; FRANCE; GENES, BRCA1; GENES, BRCA2; GENOTYPE; HUMANS; MASTECTOMY; OVARIAN NEOPLASMS; PHENOTYPE; PHYSICIAN-PATIENT RELATIONS;

EID: 33744946276     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.02.002     Document Type: Article

References (111)

1. Inserm-FNCLCC. Risques héréditaires de cancers du sein et de l'ovaire. Quelles prises en charge ? (1998), Inserm, Paris
2. Eisinger F., Alby N., Bremond A., Dauplat J., Espiè M., Janiaud P., et al. Expertise collective Inserm-FNCLCC. Recommandations sur la prise en charge des femmes ayant un risque d'origine génétique de développer un cancer du sein ou de l'ovaire. Bull. Cancer 86 (1999) 307-313
3. Hoerni B. Participation des patients à la décision en cancérologie. Bull. Cancer 89 10 (2002) 904-907
4. Peto J., Collins N., Barfoot R., Seal S., Warren W., Rahman N., et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early- onset breast cancer. J. Natl. Cancer Inst. 91 11 (1999) 943-949 [see comments]
5. Easton D.F., Ford D., Bishop D.T., and and the breast cancer linkage consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am. J. Hum. Genet. 56 (1995) 265-271
6. Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336 (1997) 1401-1408
7. Ford D., Easton D., Stratton M., Narod S., Goldgar D., Devilee P., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 62 (1998) 676-689
8. Hopper J.L., Southey M.C., Dite G.S., Jolley D.J., Giles G.G., McCredie M.R., et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol. Biomarkers Prev. 8 9 (1999) 741-747
9. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Kwan E., et al. Prevalence and Penetrance of Germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68 3 (2001) 700-710
10. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 5 (2003) 1117-1130
11. Chappuis P., Stoppa-Lyonnet D., Asselain B., and Foulkes W. The natural history of hereditary breast cancer. In: Morrison P., Hodgson S., and Naites N. (Eds). Familial breast and ovarian cancer: genetics, screening and management (2002), Cambridge Press
12. The breast cancer linkage consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91 15 (1999) 1310-1316
13. Thompson D., and Easton D.F. Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94 18 (2002) 1358-1365
14. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., and Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl. Cancer Inst. 94 18 (2002) 1365-1372
15. Seitz J.F., and Faivre J. La conférence française de consensus sur les cancers du côlon : des recommandations simples et précises. Bull. Cancer 85 4 (1998) 293-294 [The French consensus conference on cancer of the colon: simple and precise recommendations (editorial)]
16. Domchek S.M., Eisen A., Calzone K., Stopfer J., Blackwood A., and Weber B.L. Application of breast cancer risk prediction models in clinical practice. J. Clin. Oncol. 21 4 (2003) 593-601
17. Bonadona V., and Lasset C. Prédispositions héréditaires au cancer du sein : après BRCA1 et BRCA2, quel(s) autre(s) gène(s)?. Bull. Cancer 90 7 (2003) 587-594 [Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?]
18. Claus E.B. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam. Cancer 1 3-4 (2001) 197-206
19. Euhus D.M., Smith K.C., Robinson L., Stucky A., Olopade O.I., Cummings S., et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J. Natl. Cancer Inst. 94 11 (2002) 844-851
20. Page D.L., Dupont W.D., Rogers L.W., Jensen R.A., and Schuyler P.A. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76 7 (1995) 1197-1200
21. Frykberg E.R. Lobular carcinoma in situ of the breast. Breast J. 5 5 (1999) 296-303
22. Lidereau R., Eisinger F., Champeme M.H., Nogues C., Bieche I., Birnbaum D., et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 60 5 (2000) 1206-1210
23. Eisinger F., Thouvenin D., Bignon Y.J., Cuisenier J., Feingold J., Hoerni B., et al. Réflexions sur l'organisation des consultations d'oncogénétique (première étape vers la publication de bonnes pratiques cliniques). Bull. Cancer 82 (1995) 865-878
24. Wagner T., Stoppa-Lyonnet D., Fleischmann E., Muhr D., Pages S., Sandberg T., et al. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62 3 (1999) 369-376
25. Gad S., Aurias A., Puget N., Mairal A., Schurra C., Montagna M., et al. Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements. Genes Chromosomes Cancer 31 1 (2001) 75-84
26. Hogervorst F.B., Nederlof P.M., Gille J.J., McElgunn C.J., Grippeling M., Pruntel R., et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 63 7 (2003) 1449-1453
27. Peelen T., van Vliet M., Bosch A., Bignell G., Vasen H.F., Klijn J.G., et al. Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br. J. Cancer 82 1 (2000) 151-156
28. Thomas D.B., Gao D.L., Ray R.M., Wang W.W., Allison C.J., Chen F.L., et al. Randomized trial of breast self-examination in Shanghai: final results. J. Natl. Cancer Inst. 94 19 (2002) 1445-1457
29. Brekelmans C.T., Seynaeve C., Bartels C.C., Tilanus-Linthorst M.M., Meijers-Heijboer E.J., Crepin C.M., et al. Effectiveness of breast cancer surveillance in BRCA1/BRCA2 gene mutation carriers and women with high familial risk. J. Clin. Oncol. 19 4 (2001) 924-930
30. Huo Z., Giger M.L., Olopade O.I., Wolverton D.E., Weber B.L., Metz C.E., et al. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology 225 2 (2002) 519-526
31. Ziv E., Shepherd J., Smith-Bindman R., and Kerlikowske K. Mammographic breast density and family history of breast cancer. J. Natl. Cancer Inst. 95 7 (2003) 556-558
32. Boyd N.F., Byng J.W., Jong R.A., Fishell E.K., Little L.E., Miller A.B., et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J. Natl. Cancer Inst. 87 9 (1995) 670-675
33. Kolb T.M., Lichy J., and Newhouse J.H. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 225 1 (2002) 165-175
34. Tilanus-Linthorst M., Verhoog L., Obdeijn I.M., Bartels K., Menke-Pluymers M., Eggermont A., et al. A BRCA1/ BRCA2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int. J. Cancer 102 1 (2002) 91-95
35. Tristan H. Imagerie du sein. In: Inserm-FNCLCC (Ed). Risques héréditaires de cancers du sein et de l'ovaire. Quelle prise en charge ? (1998), Inserm, Paris 517-571
36. Law J. Cancers detected and induced in mammographic screening: new screening schedules and younger women with family history. Br. J. Radiol. 70 (1997) 62-69
37. Young K.C. Radiation doses in the UK trial of breast screening in women aged 40-48 years. Br. J. Radiol. 75 892 (2002) 362-370
38. Abbott D.W., Thompson M.E., Robinson-Benion C., Tomlinson G., Jensen R.A., and Holt J.T. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem. 274 26 (1999) 18808-18812
39. Elmore J.G., Barton M.B., Moceri V.M., Polk S., Arena P.J., and Fletcher S.W. Ten-year risk of false positive screening mammograms and clinical breast examinations. N. Engl. J. Med. 338 16 (1998) 1089-1096
40. Lehman C.D., White E., Peacock S., Drucker M.J., and Urban N. Effect of age and breast density on screening mammograms with false-positive findings. AJR Am. J. Roentgenol. 173 6 (1999) 1651-1655
41. Daly C.A., Apthorp L., and Field S. Second round cancers: how many were visible on the first round of the UK National Breast Screening Programme, three years earlier?. Clin. Radiol. 53 1 (1998) 25-28
42. Anaes. Évaluation clinique de la numérisation en mammographie pour le diagnostic et le dépistage du cancer du sein (2000), Anaes
43. Hermann K.P., Obenauer S., Marten K., Kehbel S., Fischer U., and Grabbe E. Average glandular dose with amorphous silicon full-field digital mammography - Clinical results. Rofo Fortschr. Geb. Rontgenstr. Neuen Bildgeb. Verfahr. 174 6 (2002) 696-699
44. Huo Z., Giger M.L., Vyborny C.J., and Metz C.E. Breast cancer: effectiveness of computer-aided diagnosis observer study with independent database of mammograms. Radiology 224 2 (2002) 560-568
45. Brem R.F., Baum J., Lechner M., Kaplan S., Souders S., Naul L.G., et al. Improvement in sensitivity of screening mammography with computer-aided detection: a multiinstitutional trial. AJR Am. J. Roentgenol. 181 3 (2003) 687-693
46. Kaplan S.S. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 221 3 (2001) 641-649
47. Kuhl C.K., Schrading S., Leutner C.C., Morakkabati N., Trog D., Schmutzler R., et al. Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial. J. Clin. Oncol. 21 23 Suppl (2003) 238
48. Kriege M., Brekelmans C.T., Boetes C., Rutgers E.J., Oosterwijk J.C., Tollenaar R.A., et al. MRI screening for breast cancer in women with high familial and genetic risk: first results of the Dutch MRI screening study (MRISC). J. Clin. Oncol. 21 23 Suppl (2003) 238
49. Warner E., Plewes D.B., Shumak R.S., Catzavelos G.C., Di Prospero L.S., Yaffe M.J., et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J. Clin. Oncol. 19 15 (2001) 3524-3531
50. Podo F., Sardanelli F., Canese R., D'Agnolo G., Natali P.G., Crecco M., et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J. Exp. Clin. Cancer Res. 21 3 Suppl (2002) 115-124
51. Eisinger F., Julian-Reynier C., and Sobol H. Re: biologic characteristics of interval and screen-detected breast cancers. J. Natl. Cancer Inst. 92 18 (2000) 1533-1534
52. Noel A., Stines J., Heid P., Lisbona A., Verdun F.R., Barreau B., et al. Recommandations pour un programme d'assurance de qualité en mammographie numérique. J. Radiol. 84 6 (2003) 723-729 [Recommendations for a QA program for digital mammography]
53. Marchbanks P.A., McDonald J.A., Wilson H.G., Folger S.G., Mandel M.G., Daling J.R., et al. Oral contraceptives and the risk of breast cancer. N. Engl. J. Med. 346 26 (2002) 2025-2032
54. de Bock G.H., Tollenaar R.A., Papelard H., Vliet Vlieland T.P., Devilee P., Cornelisse C.J., et al. Re: oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 95 13 (2003) 1011-1012 (author reply 1012-3)
55. Narod S.A., Risch H., Moslehi R., Dorum A., Neuhausen S., Olsson H., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary ovarian cancer clinical study group. N. Engl. J. Med. 339 7 (1998) 424-428
56. Burke W. Oral contraceptives and breast cancer: a note of caution for high-risk women. JAMA 284 14 (2000) 1837-1838
57. Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362 9382 (2003) 419-427
58. Decensi A., Galli A., and Veronesi U. HRT opposed to low-dose tamoxifen (HOT study): rationale and design. Recent Results Cancer Res. 163 (2003) 104-111 (discussion 264-6)
59. Narod S.A., Brunet J.S., Ghadirian P., Robson M., Heimdal K., Neuhausen S.L., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group. Lancet 356 9245 (2000) 1876-1881
60. Fisher B., Costantino J., Wickerham D., Redmond C., Kavanah M., Cronin W., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
61. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 9122 (1998) 98-101
62. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352 (1998) 93-97
63. King M.C., Wieand S., Hale K., Lee M., Walsh T., Owens K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286 18 (2001) 2251-2256
64. Cuzick J. A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials. Ann. N. Y. Acad. Sci. 949 (2001) 123-133
65. Foulkes W.D., Goffin J., Brunet J.-S., Bégin L.R., Wong N., and Chappuis P.O. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of Estrogen Receptor Status. J. Natl. Cancer Inst. 94 (2002) 1504-1506
66. Chlebowski R.T., Col N., Winer E.P., Collyar D.E., Cummings S.R., Vogel III V.G., et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J. Clin. Oncol. 20 15 (2002) 3328-3343
67. Willemsen H.W., Kaas R., Peterse J.H., and Rutgers E.J. Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy. Eur. J. Surg. Oncol. 24 4 (1998) 331-332
68. Meijers-Heijboer H., van Geel B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345 3 (2001) 159-164
69. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93 21 (2001) 1633-1637
70. Grann V.R., Jacobson J.S., Whang W., Hershman D., Heitjan D.F., Antman K.H., et al. Prevention with tamoxifen or other hormones vs prophylactic surgery in BRCA1/BRCA2-positive women: a decision analysis. Cancer J. Sci. Am. 6 1 (2000) 13-20
71. van Roosmalen M.S., Verhoef L.C., Stalmeier P.F., Hoogerbrugge N., and van Daal W.A. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J. Clin. Oncol. 20 8 (2002) 2092-2100
72. Wagner T.M., Moslinger R., Langbauer G., Ahner R., Fleischmann E., Auterith A., et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br. J. Cancer 82 7 (2000) 1249-1253
73. Goin M.K., and Goin J.M. Psychological reactions to prophylactic mastectomy synchronous with contralateral breast reconstruction. Plast. Reconstr. Surg. 70 3 (1982) 355-359
74. Stefanek M.E., Helzlsouer K.J., Wilcox P.M., and Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev. Med. 24 4 (1995) 412-419
75. Frost M.H., Schaid D.J., Sellers T.A., Slezak J.M., Arnold P.G., Woods J.E., et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284 3 (2000) 319-324
76. Blanchard D.K., and Hartmann L.C. Prophylactic surgery for women at high risk for breast cancer. Clin. Breast Cancer 1 2 (2000) 127-134 (discussion 135)
77. Josephson U., Wickman M., and Sandelin K. Initial experiences of women from hereditary breast cancer families after bilateral prophylactic mastectomy: a retrospective study. Eur. J. Surg. Oncol. 26 4 (2000) 351-356
78. Meiser B., Butow P., Friedlander M., Schnieden V., Gattas M., Kirk J., et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J. Clin. Oncol. 18 11 (2000) 2250-2257 [In Process Citation]
79. Houn F., Helzlouer K.J., Friedman N.B., and Stefanek M.E. The Practice of Prophylavtic Mastectomy: a survey of maryland surgeons. Am. J. Public Health 85 (1995) 801-805
80. Borgen P.I., Hill A.D., Tran K.N., Van Zee K.J., Massie M.J., Payne D., et al. Patient regrets after bilateral prophylactic mastectomy. Ann. Surg. Oncol. 5 7 (1998) 603-606
81. Schrag D., Kuntz K.M., Garber J.E., and Weeks J.C. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283 5 (2000) 617-624
82. Contant C.M., Menke-Pluijmers M.B., Seynaeve C., Meijers-Heijboer E.J., Klijn J.G., Verhoog L.C., et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur. J. Surg. Oncol. 28 6 (2002) 627-632
83. Petit J.Y., and Greco M. Quality control in prophylactic mastectomy for women at high risk of breast cancer. Eur. J. Cancer 38 1 (2002) 23-26
84. Barton Jr. F.E., English J.M., Kingsley W.B., and Fietz M. Glandular excision in total glandular mastectomy and modified radical mastectomy: a comparison. Plast. Reconstr. Surg. 88 3 (1991) 389-392 (discussion 393-4)
85. Rebbeck T.R., Levin A.M., Eisen A., Snyder C., Watson P., Cannon-Albright L., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst. 91 (1999) 1475-1479
86. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 21 (2002) 1616-1622
87. Eisinger F., Stoppa-Lyonnet D., Lasset C., Vennin P., Chabal F., Nogues C., et al. Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. Fam. Cancer 1 3-4 (2001) 157-162
88. Taylor K.J., and Schwartz P.E. Cancer screening in a high-risk population: a clinical trial. Ultrasound Med. Biol. 27 4 (2001) 461-466
89. Sato S., Yokoyama Y., Sakamoto T., Futagami M., and Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 89 3 (2000) 582-588
90. DePriest P.D., and DeSimone C.P. Ultrasound screening for the early detection of ovarian cancer. J. Clin. Oncol. 21 10 Suppl (2003) 194-199
91. van Nagell Jr. J.R., DePriest P.D., Reedy M.B., Gallion H.H., Ueland F.R., Pavlik E.J., et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77 3 (2000) 350-356
92. Laframboise S., Nedelcu R., Murphy J., Cole D.E., and Rosen B. Use of CA-125 and ultrasound in high-risk women. Int. J. Gynecol. Cancer 12 1 (2002) 86-91
93. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 9306 (2002) 572-577
94. Diamandis E.P. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360 9327 (2002) 170 (author reply 170-1)
95. Chang H.W., Lee S.M., Goodman S.N., Singer G., Cho S.K., Sokoll L.J., et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl. Cancer Inst. 94 22 (2002) 1697-1703
96. Rutter J.L., Wacholder S., Chetrit A., Lubin F., Menczer J., Ebbers S., et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J. Natl. Cancer Inst. 95 14 (2003) 1072-1078
97. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346 21 (2002) 1609-1615
98. Wooster R., and Weber B.L. Breast and ovarian cancer. N. Engl. J. Med. 348 23 (2003) 2339-2347
99. Elit L., Esplen M.J., Butler K., and Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam. Cancer 1 3-4 (2001) 149-156
100. Elit L., Rosen B., Goel V., McLaughlin J., Fung M.K., Shime J., et al. Prophylactic oophorectomy in Ontario. Fam. Cancer 1 3-4 (2001) 143-148
101. Zalel Y., Lurie S., Beyth Y., Goldberger S., and Tepper R. Is it necessary to perform a prophylactic oophorectomy during hysterectomy?. Eur. J. Obstet. Gynecol. Reprod. Biol. 73 1 (1997) 67-70
102. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N. Engl. J. Med. 346 21 (2002) 1660-1662
103. Eccles D., Simmonds P., Goddard J., Coultas M., Hodgson S., Lalloo F., et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam. Cancer 1 2 (2001) 65-72
104. Haffty B.G., Harrold E., Khan A.J., Pathare P., Smith T.E., Turner B.C., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/BRCA2 status. Lancet 359 9316 (2002) 1471-1477
105. Pierce L.J., Strawderman M., Narod S.A., Oliviotto I., Eisen A., Dawson L., et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/BRCA2 mutations. J. Clin. Oncol. 18 19 (2000) 3360-3369
106. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., and Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22 5 (2003) 1169-1173
107. Moller P., Borg A., Evans D.G., Haites N., Reis M.M., Vasen H., et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int. J. Cancer 101 6 (2002) 555-559
108. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., and Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 9 (2003) 2187-2195
109. Labrie F. Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate 43 3 (2000) 215-222
110. Etzioni R., Penson D.F., Legler J.M., Di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from u.s. Prostate cancer incidence trends. J. Natl. Cancer Inst. 94 13 (2002) 981-990
111. Edwards S.M., Kote-Jarai Z., Meitz J., Hamoudi R., Hope Q., Osin P., et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet. 72 1 (2003) 1-12